Related Experiment Video
Updated: Sep 18, 2025
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
304
Epithelial Cell Dysfunction in Pulmonary Fibrosis: Mechanisms, Interactions, and Emerging Therapeutic Targets
1Department of Physiology, School of Medicine, Southeast University, Nanjing 210009, China.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2025
Summary
Pulmonary fibrosis (PF) involves epithelial cell dysfunction and excessive extracellular matrix (ECM) deposition. Targeting epithelial cell pathways offers new therapeutic strategies for this progressive lung disease.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Molecular Biology
Background:
- Pulmonary fibrosis (PF) is a fatal lung disease marked by chronic epithelial injury and extracellular matrix (ECM) deposition.
- Epithelial cell dysfunction, including epithelial-mesenchymal transition (EMT), oxidative stress, and altered immune interactions, is central to PF pathogenesis.
- Single-cell studies reveal pro-fibrotic subpopulations within type 2 alveolar (AT2) cells.
Purpose of the Study:
- To review the molecular mechanisms underlying epithelial dysfunction in pulmonary fibrosis progression.
- To highlight key regulatory pathways (TGF-β, Wnt, Notch, miRNA) involved in fibrosis.
- To explore emerging epithelial-targeted therapies for clinical translation.
Main Methods:
- Literature review focusing on molecular mechanisms and therapeutic strategies in pulmonary fibrosis.
- Analysis of signaling pathways (TGF-β, Wnt, Notch) and miRNA networks.
- Examination of metabolic and epigenetic alterations in epithelial cells during PF.
Main Results:
- Epithelial cell dysfunction, characterized by EMT, oxidative stress, and immune dysregulation, drives PF.
- Distinct AT2 cell subpopulations exhibit pro-fibrotic characteristics.
- Metabolic and epigenetic changes in epithelial cells present therapeutic targets.
Conclusions:
- Understanding epithelial dysfunction mechanisms is crucial for developing anti-fibrosis strategies.
- Targeting key signaling pathways and molecular networks offers potential for precision medicine in PF.
- Emerging therapies, including FDA-approved drugs and novel inhibitors, show promise for clinical translation.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K
01:20COPD: Pathogenesis and Clinical Features
535
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
535
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.9K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.9K
01:23Cystic Fibrosis: Pathogenesis
369
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
369
01:24Cystic Fibrosis: Management
228
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
228
01:09Introduction to Fibroblasts
3.2K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.2K